Cooperative Agreement U01FD007172

This STTR Phase I project grant from the National Center for Advancing Translational Sciences (NCATS) (CFDA 93.350) provides $649,264 to Grayrain, LLC to develop a novel platform for statistical obfuscation and de-identification of sensitive clinical data, including structured tabular data, text, and images. The goal is to enable secure data sharing and analytics while protecting patient privacy and personal health information. The technology proposed aims to produce de-identified synthetic data...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Yale University totals $167,500 and will be executed from September 2023 through August 2025. The primary objectives are to: Develop deep neural network-based emulation analysis methods and software to objectively quantify the relative effectiveness of drugs, devices, and treatment procedures on cancer prognosis, especially when randomized clinical trials are not feasible. The...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop an innovative liquid biopsy approach using circulating tumor DNA (ctDNA) fragmentomics to monitor metastatic castration-resistant prostate cancer (mCRPC). The $680,453 award to the University of Wisconsin-Madison aims to: Determine if baseline ctDNA fragmentomics scores are prognostic biomarkers in mCRPC, Detect diverse androgen...

The Defense Health Agency awarded a $3,644,169 Project Grant to the ECOG-ACRIN Medical Research Foundation, Inc. to advance precision and equity in breast cancer care. This funding, provided through the Military Medical Research and Development program (CFDA 12.420), supports a 4-year clinical research extension to the TAILORx study, which aims to improve personalized treatment for breast cancer patients. As a subrecipient, the Foundation has also supported research at Dana-Farber Cancer...

The federal Cooperative Agreement award of $1,105,466.00 was granted by the National Center for Advancing Translational Sciences (NCATS) on August 1, 2024 to The Research Foundation For The State University Of New York (RF SUNY). The purpose of this award, under CFDA program 93.350, is to conduct a series of 3 randomized controlled trials (RCTs) evaluating the impact of remote versus in-person clinical trial methods on key trial efficiency and quality outcomes, such as participant accrual,...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $273,188 to Docare LLC, a small disadvantaged business located in San Juan, Puerto Rico, aims to develop a large language model and communication optimization tools to improve clinical trial participant engagement and retention. The project will use unsupervised machine learning and operations research techniques to analyze communication data from multiple clinical trials,...

This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Medical Library Assistance (CFDA 93.879) federal grant program provides $729,821 to Boston Children's Hospital to develop artificial intelligence (AI) and machine learning (ML) methods for real-time monitoring and updating of clinical decision support (CDS) systems. The goal is to reduce downstream health disparities that may arise from biases in the underlying data used to train these AI/ML...

This $627,833 Project Grant award from the National Cancer Institute's Cancer Biology Research Program (CFDA 93.396) aims to develop an informatics platform that integrates molecular and pathological data from various lung cancer preclinical models and patient tumors. The key products and services to be delivered include: Harmonizing molecular profiling datasets from multiple lung cancer preclinical models and implementing statistical methods for cross-study validation and quality control....

This Project Grant award of $358,000 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support research to characterize and mitigate nonresponse in patient-reported outcome (PRO) data collected as part of routine cancer care. The overarching goal is to enhance the representativeness of PRO data to improve its utility for promoting high-value, equitable patient-centered care in cancer clinics. The research will (1) characterize...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $400,000 to develop and evaluate a customized version of the "MYTRIALS" integrated remote biomarker capture system to support decentralized clinical trials for substance use disorders (SUDs). The key objectives are to refine the existing MYTRIALS prototype to better meet the needs of SUD decentralized trials, and then conduct a...